The Effect of Dapagliflozin on Ultrafiltration Among Peritoneal Dialysis Patients
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
Patients with average or high average peritoneal glucose transport status be included in the
study as mentioned in the inclusion and exclusion criteria.
The change in peritoneal glucose transport will be evaluated before and after one month
treatment with 10 mg of Dapagliflozin.
Peritoneal Equilibration Test (PET) test for patients before and after Dapagliflozin use and
volume status of patients as measured by ultrafiltration from peritoneal dialysis exchanges.
The aim of the trial is to determine whether dapagliflozin can decrease glucose absorption
from peritoneal fluid and reduce plasma glucose absorption from the PD fluid and thus improve
ultrafiltration with a reduction in intraperitoneal glucose exposure